12:00 AM
 | 
Sep 17, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Regorafenib regulatory update

Bayer said the Japanese Ministry of Health, Labor and Welfare (MHLW) granted Priority Review for an NDA for regorafenib to treat unresectable, advanced or recurrent colorectal cancer. The application, which was submitted at the end of July, is based on data from...

Read the full 188 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >